Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$2.84 CAD
Change Today -0.01 / -0.35%
Volume 1.1K
As of 2:52 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

fennec pharmaceuticals inc (FRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/27/14 - C$7.77
52 Week Low
12/23/14 - C$2.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

fennec pharmaceuticals inc (FRX) Related Businessweek News

No Related Businessweek News Found

fennec pharmaceuticals inc (FRX) Details

Fennec Pharmaceuticals Inc., together with its subsidiaries, operates as a biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. Its lead product candidates include Sodium Thiosulfate, a water soluble thiol compound, which is in phase III clinical trials that act as a chemical reducing agent for the prevention of cisplatin induced hearing loss or ototoxicity in children; and Eniluracil, an oral irreversible dihydropyrimidine dehydrogenase inhibitor for the rapid break down of 5-FU in the body, which has completed phase II clinical trials for the treatment of metastatic breast cancer. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

1 Employees
Last Reported Date: 03/31/15
Founded in 1996

fennec pharmaceuticals inc (FRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $140.0K
Interim Chief Financial Officer
Total Annual Compensation: $26.5K
Compensation as of Fiscal Year 2013.

fennec pharmaceuticals inc (FRX) Key Developments

Fennec Pharmaceuticals Inc. Reports Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Fennec Pharmaceuticals Inc. reported consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of $790,000 compared to $416,000 reported a year ago. Net income was $1,388,000 or $0.14 per basic share compared to $1,112,000 or $0.12 per basic share reported a year ago. The increase in the net loss from operations excluding the non-cash impact of derivatives is primarily due to an increase in general and administrative non-cash expenses associated with equity based compensation. For the year, the company reported loss from operations of $2,877,000 compared to $1,931,000 reported a year ago. Net loss was $2,176,000 or $0.22 per basic share compared to net income of $1,845,000 or $0.19 per basic share reported a year ago. The increase in the net loss from operations excluding the non-cash impact of derivatives is primarily due to the non-cash expense of issuing equity based compensation and select corporate administrative expenses tied to the 2014 warrant exchange, reverse stock split and corporate name change.

Fennec Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt

Fennec Pharmaceuticals Inc. filed its 10-K on Mar 31, 2015 for the period ending Dec 31, 2014. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Fennec Pharmaceuticals Inc. Announces Independent Data Monitoring Committee Recommends the Continuation of SIOPEL 6 Phase 3 Clinical Trial

Fennec Pharmaceuticals Inc. announced that the IDMC overseeing the SIOPEL 6 phase 3 clinical trial recommended that the study be continued as planned. The IDMC has been established to assess any potential concern of an adverse effect of STS on the efficacy of the cisplatin chemotherapy and to review safety according to protocol pre-specified patient numbers. Previously, the IDMC reached similar conclusion after reviewing the safety of 20, 40, 60 and 80 patients and their current recommendation on 100 patients to continue the clinical trial represents the last and final safety review. SIOPEL 6 is a multi-centre open label randomized phase 3 study evaluating the efficacy of STS in reducing ototoxicity in patients receiving cisplatin monotherapy for standard risk hepatoblastoma. From the beginning of 2007 to the end 2014, 45 sites from 12 countries enrolled 113 evaluable patients. The study is closed to recruitment and all protocol pre-specified IDMC safety reviews are now complete. The primary efficacy hearing endpoint analysis can be performed once patients have reached 3.5 years of age and an audiometry test can be carried out.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRX:CN C$2.84 CAD -0.01

FRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation FRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 40.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FENNEC PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at